LENZ Therapeutics Inc (NAS:LENZ)

Q3 2025 LENZ Therapeutics Inc Earnings Call Transcript

Nov 5, 2025 / 01:30 PM GMT

Release Date Price: $21.47 (-23.46%)

Transcript 10-Q8-K

Key Points

Positve

LENZ Therapeutics Inc (LENZ) received FDA approval for its eye drop product, marking a significant milestone.
The company successfully launched its product in the US, with over 5,000 prescriptions filled in October.
LENZ Therapeutics Inc (LENZ) achieved 90% awareness among eye care professionals shortly after launch.
The company raised over $123 million through a direct placement, strengthening its financial position.
LENZ Therapeutics Inc (LENZ) has partnered with Sarah Jessica Parker for a direct-to-consumer campaign, enhancing brand visibility.

Negative

The product launch is still in its early stages, with full retail pharmacy availability not yet achieved.
There are reports of transient redness and stinging as side effects, which may affect patient experience.
The company faces challenges in converting sample distributions into paid prescriptions.
LENZ Therapeutics Inc (LENZ) has increased SG&A expenses significantly, impacting financials.
The company is heavily reliant on optometrists for prescriptions, which may limit market reach.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LENZ.OQ - Lenz Therapeutics Inc
Q3 2025 LENZ Therapeutics Inc Earnings Call
Nov 05, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, ladies and gentlemen, and welcome to the Lenss Therapeutic 3rd quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode.

Following prepared remarks from management, we'll conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this call is being recorded. At this time, I'd like to turn the call over to Dan Chevellard, Chief Financial Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good morning and thank you for joining us today.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.